Testing a new drug with radiation for advanced breast cancer brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This study looks at how well a new anti-tumor drug works when given along with radiation therapy for people whose advanced breast cancer has spread to the brain. It may help the radiation work better and control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced breast cancer that has spread to the brain and cannot be removed with surgery.
- Your doctor plans to treat the brain tumors with radiation therapy.
- You are taking or will take a specific type of anti-tumor drug (such as an ADC, CDK4/6 inhibitor, TKI, certain chemotherapies, bevacizumab, or immunotherapy) within 3 weeks before, during, or after radiation.
- You do not have cancer spread to the lining of the brain and spinal cord (leptomeningeal disease).
- Your neurological symptoms from the brain tumors are not too severe to handle radiation therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
This trial tests whether adding anlotinib (a targeted therapy) to standard radiation can better control breast cancer that has spread to the brain. It is for people with HER2-negative breast cancer and at least one brain tumor seen on MRI.
This trial tests a new drug (SHR-A1811) combined with radiation therapy for people with HER2-positive or HER2-low breast cancer that has spread to the brain. It aims to see if the combination can better control brain metastases.
Hear when a new Advanced Breast Cancer Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.